Bal Pharma Limited has informed the Exchange about Copy of Newspaper Publication of audited financial results of the Company for the quarter and financial year ended 31.03.2026.
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bal Pharma Limited has published its audited standalone and consolidated financial results for Q4 and full year FY26 ended March 31, 2026. Standalone total income from operations was Rs 49,427.06 lakh for Q4 and Rs 1,98,712.27 lakh for the full year. Standalone net profit after tax was Rs 2,674.90 lakh for Q4 and Rs 12,702.84 lakh for FY26. Consolidated net profit after tax was Rs 511.99 lakh for Q4 and Rs 10,001.64 lakh for FY26. The Board also approved a final dividend of Rs 2.5 per equity share of Rs 10 each for FY26. The results were approved by the Board on May 27, 2026 and published in Financial Express and Sanjevani newspapers on May 29, 2026.
The company reported healthy year-on-year growth in standalone revenue, showing improved operational performance. The declared dividend signals management confidence in cash flow generation. Shareholders can expect the stock to reflect the full-year earnings trajectory in upcoming trading sessions.